Brickell’s Phase III Data Sets Up NDA Filing In Axillary Hyperhidrosis

Meeting all primary and secondary endpoints in a pair of pivotal trials, Brickell says sofpironium bromide gel will be ready for FDA filing in mid-2022. The topical is already approved in Japan as Ecclock.

Diagnosis - Hyperhidrosis. Medical Concept with Blurred Text, Stethoscope, Pills and Syringe on Green Background. Selective Focus. 3D Render.
Brickell hopes to improve the standard of care for axillary hyperhidrosis

Brickell Biotech, Inc. said on 7 October that it plans to file a new drug application by mid-2022 for sofpironium bromide gel 15% (SB gel) to treat primary axillary hyperhidrosis after the anticholinergic met the primary endpoint and all secondary endpoints in a pair of pivotal Phase III studies. On a same-day investor call, CEO Robert Brown said SB gel could offer a best-in-class treatment option for a disease that affects an estimated 15 million Americans.

In the Cardigan I and Cardigan II trials, the topical dosed once each night at bedtime met the primary endpoint...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

More from R&D